Ireland· IE-PA-EU/1/25/2002/001
Anktiva 400µg/0.4 ml Intravesical solution
A nogapendekin alfa and inbakicept product containing nogapendekin alfa + inbakicept, registered in Ireland by Serum Life Science Europe GmbH. The same ATC class is registered in 7 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Nogapendekin alfa and inbakicept is registered in 7 of 19 countries.
Countries holding a registration under ATC L03AC03 (nogapendekin alfa and inbakicept), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 5 of them publish a price we can compare per daily dose
Nogapendekin alfa and inbakicept · ATC L03AC03
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Nogapendekin alfa + Inbakicept
- Manufacturer
- Serum Life Science Europe GmbH
- Country
- Ireland (IE)
- ATC code
- L03AC03
- ATC class
- Nogapendekin alfa and inbakicept
- Defined daily dose
- 12.5 mcg, intravesikal
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/25/2002/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L03AC03
Nogapendekin alfa and inbakicept, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/13de28ce-7470-4c26-b731-d5b1e1e16aa5 GET /v1/drugs/13de28ce-7470-4c26-b731-d5b1e1e16aa5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Intravesical solution",
"routes": [
"Intravesical use"
],
"source": "hpra",
"atc_all": [
"L03AC03"
],
"strength": null,
"pa_number": "EU/1/25/2002/001",
"substances": [
"Nogapendekin alfa",
"Inbakicept"
],
"legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "16/02/2026",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about nogapendekin alfa and inbakicept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.